Aprea Therapeutics (APRE) Liabilities and Shareholders Equity (2018 - 2026)

Aprea Therapeutics (APRE) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $47.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 135.45% year-over-year to $47.6 million; the TTM figure through Mar 2026 stood at $95.2 million (down 5.82% YoY), while the FY2025 annual figure was $15.9 million, down 33.55% from the prior year.
• Liabilities and Shareholders Equity climbed to $47.6 million in Q1 2026 per APRE's latest filing, from $15.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $50.3 million in Q1 2022 and bottomed at $14.3 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $29.0 million across 5 years, with a median of $28.7 million in 2023.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 46.93% — and 2026, when it soared 135.45%.
• Aprea Therapeutics' Liabilities and Shareholders Equity stood at $30.2 million in 2022, then slipped by 24.89% to $22.7 million in 2023, then climbed by 5.87% to $24.0 million in 2024, then plunged by 33.55% to $15.9 million in 2025, then jumped by 198.82% to $47.6 million in 2026.
• Business Quant data shows APRE's Liabilities and Shareholders Equity at $47.6 million in Q1 2026, $15.9 million in Q4 2025, and $14.3 million in Q3 2025.